Condition: Moderate-to-severe Chronic Plaque Psoriasis · Sponsor: Jiangsu HengRui Medicine Co., Ltd.
This is a multi-regional, randomized, double-blind, placebo-controlled, clinical trial to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SHR-1314 in adults with moderate-to-severe plaque psoriasis.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Elite Clinical Studies, LLC | Phoenix, Arizona, United States | — |
| Anaheim Clinical Trials | Anaheim, California, United States | — |
| Revival Research | Doral, Florida, United States | — |
| Indago Research and Health Center - Emergency Medicine | Hialeah, Florida, United States | — |
| Great Lakes Clinical Trials LLC | Chicago, Illinois, United States | — |
| Clinical Partners, LLC | Johnston, Rhode Island, United States | — |
| Center for Clinical Studies | Houston, Texas, United States | — |
| Center for Clinical Studies | Webster, Texas, United States | — |
| St George Dermatology and Skin Cancer Centre - Dermatology | Kogarah, New South Wales, Australia | — |
| Westmead Hospital | Westmead, New South Wales, Australia | — |
| Veracity Clinical Research Pty Ltd | Woolloongabba, Queensland, Australia | — |
| Sinclair Dermatology - Dermatology | East Melbourne, Victoria, Australia | — |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03463187